Search

Your search keyword '"Noblet, Bénédicte"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Noblet, Bénédicte" Remove constraint Author: "Noblet, Bénédicte"
16 results on '"Noblet, Bénédicte"'

Search Results

1. Dual regulation of TxNIP by ChREBP and FoxO1 in liver

2. Corrigendum to: ‘Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target’ [J Hepatol 2021 (74) 1155-1166]

4. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target

5. BAP1 mutations define a specific subgroup of hepatocellular carcinoma with fibrolamellar features and PKA activation Short title: BAP1 HCC have FLC features and activate PKA

6. BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features

7. Corrigendum to: “BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA” [J Hepatol (2020) 1–13]

8. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA

10. Volasertib preclinical activity in high-risk hepatoblastoma

11. Insulin activates hepatic Wnt/β-catenin signaling through stearoyl-CoA desaturase 1 and Porcupine

12. Abstract 4628: Tailoring personalized strategies for children with treatment-refractory liver cancer

14. FRI515 - BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features.

15. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

16. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.

Catalog

Books, media, physical & digital resources